MECHELEN, BELGIUM--(Marketwired - July 23, 2013) - Galapagos NV (Euronext: GLPG) announced
the achievement of a late stage discovery milestone for small molecules
a novel target in the osteoarthritis (OA) alliance with Servier. This
triggered a payment to Galapagos of EUR3 million and will contribute
revenues in the first half of 2013.
"Galapagos already delivered multiple compounds against different OA
into late discovery and selected a preclinical candidate last year.
achievement is consistent with our strategy to move multiple, novel
mechanism-of-action programs toward the clinic, thereby increasing the
chances of success
in disease areas with high unmet medical needs," said Onno van de Stolpe,
"Galapagos is delivering what we aimed for in our alliance to discover new
therapies in osteoarthritis. Servier is committed to developing medicines
actually address the causes of osteoarthritis, a debilitating illness for
no disease-modifying treatment is available," said Dr Patricia
Belissa-Mathiot, Director of Rheumatology Innovative Pole.
In July 2010, Servier and Galapagos announced their alliance to develop new
medicines for the treatment of osteoarthritis (OA). Galapagos is
for the discovery and development of new candidate drugs against novel
and Servier has an exclusive option to license these after the
Phase 1 clinical trials. Galapagos is eligible to receive up to EUR290
success-based milestones, plus royalties on commercial sales. Galapagos
retains exclusive US commercialization rights to all commercial compounds.
Servier is a privately-run research based pharmaceutical company with a
turnover of EUR3.9 billion. Servier reinvests 25% of its turnover in
Development in cardiovascular, metabolic, neurological, psychiatric and
joint diseases as well as oncology. Servier is established in 140
worldwide with over 20,000 employees. More info at: www.servier.com
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline of five clinical, six
pre-clinical, and 30 discovery small-molecule and antibody programs
in cystic fibrosis, inflammation,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
of rheumatoid arthritis and potentially other inflammatory diseases,
in Phase 2B studies in RA and about to enter Phase 2 studies in
disease. AbbVie and Galapagos signed a worldwide license agreement
AbbVie will be responsible for further development and commercialization
Phase 2B. Galapagos has another selective JAK1 inhibitor in Phase 2 in
and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by
2012). GLPG0187 is a novel integrin receptor antagonist currently in a
1B patient study in metastasis. GLPG0974 is the first inhibitor of FFA2
evaluated clinically for the treatment of IBD; this program is currently
Proof of Concept Phase 2 study. GLPG1205 is a first-in-class molecule
targets inflammatory disorders and is currently in a First-in-Human
The Galapagos Group, including fee-for-service companies BioFocus,
Fidelta, has 800 employees and operates facilities in five countries,
global headquarters in Mechelen, Belgium. Further information at:
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly disclaims
obligation to update any such forward-looking statements in this document
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
Galapagos delivers novel osteoarthritis molecules in alliance:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE